Abbott Depakote approved for chronic migraine prophylaxis.
Executive Summary
ABBOTT DEPAKOTE FOR MIGRAINE PROPHYLAXIS APPROVED MARCH 18 as a daily therapy for adults, Abbott announced March 29. Abbott filed the supplemental NDA for an anti-migraine indication for Depakote tablets (divalproex sodium) June 30, 1994. The company suggested that Depakote would be targeted at migraineurs who do not respond to medication once a migraine attack is under way, or at those people who suffer more than two migraines per month.